Sp385
TOP 3-5 TIPS FOR SURVIVING THE FIRST YEARS IN CLINICAL PRACTICE
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
The purpose of this session is to provide early career and trainee gastroenterologist with tips and strategies for having successful first few years in clinical practice. This session will discuss topics that are pertinent to all gastroenterologists including medical-legal issues (standardization of care, litigation, best practice), navigating difficult conversations, and tips that are specific to the various GI practice types. Attendees will receive high-yield and relevant information from respected AGA leaders in a format that is interactive and engaging.
The purpose of this session is to provide early career and trainee gastroenterologist with tips and strategies for having successful first few years in clinical practice. This session will discuss topics that are pertinent to all gastroenterologists including medical-legal issues (standardization of care, litigation, best practice), navigating difficult conversations, and tips that are specific to the various GI practice types. Attendees will receive high-yield and relevant information from respected AGA leaders in a format that is interactive and engaging.
Presenter
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
PANEL DISCUSSION
The purpose of this session is to provide early career and trainee gastroenterologist with tips and strategies for having successful first few years in clinical practice…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
